Metabolic abnormalities: Triglyceride and low-density lipoprotein

Endocrinology and Metabolism Clinics of North America

Volumn 33, Issue 2, 2004, Pages 405-415

  Krauss, Ronald M ^a,b,c   Siri, Patty W ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN; COLESTYRAMINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PROTEIN SUBUNIT; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DYSLIPIDEMIA; GEL ELECTROPHORESIS; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; METABOLIC DISORDER; METABOLIC SYNDROME X; NUCLEAR MAGNETIC RESONANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPECTROSCOPY; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION;

HUMANS; LIPOPROTEINS, LDL; METABOLIC SYNDROME X; TRIGLYCERIDES;

EID: 2542478175     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2004.03.016     Document Type: Review

References (56)

1. Laws A., Hoen H.M., Selby J.V., Saad M.F., Haffner S.M., Howard B.V. Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status: relation to plasma triglyceride and apolipoprotein B concentrations. Insulin resistance atherosclerosis study (IRAS) investigators. Arterioscler Thromb Vasc Biol. 17:(1):1997;64-71
2. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 95:(5):1995;2409-2415
3. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 7:(8):2001;941-946
4. Fisher E.A., Ginsberg H.N. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem. 277:(20):2002;17377-17380
5. Ginsberg H.N. New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation. 106:(16):2002;2137-2142
6. Krauss R.M., Burke D.J. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 23:(1):1982;97-104
7. Alaupovic P. The concept of apolipoprotein-defined lipoprotein families and its clinical significance. Curr Atheroscler Rep. 5:(6):2003;459-467
8. Berneis K.K., Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 43:(9):2002;1363-1379
9. Packard C.J., Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 17:(12):1997;3542-3556
10. Karpe F., Tornvall P., Olivecrona T., Steiner G., Carlson L.A., Hamsten A. Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein. Atherosclerosis. 98:(1):1993;33-49
11. Musliner T.A., Herbert P.N., Kingston M.J. Lipoprotein substrates of lipoprotein lipase and hepatic triacylglycerol lipase from human post-heparin plasma. Biochim Biophys Acta. 575:(2):1979;277-288
12. Deckelbaum R.J., Granot E., Oschry Y., Rose L., Eisenberg S. Plasma triglyceride determines structure-composition in low and high density lipoproteins. Arteriosclerosis. 4:(3):1984;225-231
13. Sakai N., Matsuzawa Y., Hirano K., Yamashita S., Nozaki S., Ueyama Y., et al. Detection of two species of low density lipoprotein particles in cholesteryl ester transfer protein deficiency. Arterioscler Thromb. 11:(1):1991;71-79
14. Ehnholm C., Mahley R.W., Chappell D.A., Weisgraber K.H., Ludwig E., Witztum J.L. Role of apolipoprotein E in the lipolytic conversion of beta-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia. Proc Natl Acad Sci U S A. 81:(17):1984;5566-5570
15. Demant T., Bedford D., Packard C.J., Shepherd J. Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects. J Clin Invest. 88:(5):1991;1490-1501
16. Austin M.A., King M.C., Vranizan K.M., Krauss R.M. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 82:(2):1990;495-506
17. Austin M.A. Genetic and environmental influences on LDL subclass phenotypes. Clin Genet. 46:(1 Spec No):1994;64-70
18. Nieves D.J., Cnop M., Retzlaff B., Walden C.E., Brunzell J.D., Knopp R.H., et al. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes. 52:(1):2003;172-179
19. Reaven G.M., Chen Y.D., Jeppesen J., Maheux P., Krauss R.M. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest. 92:(1):1993;141-146
20. Krauss R.M. Dietary and genetic effects on low-density lipoprotein heterogeneity. Annu Rev Nutr. 21:2001;283-295
21. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 3:(2):1996;213-219
22. Jeppesen J., Hein H.O., Suadicani P., Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen male study. Circulation. 97:(11):1998;1029-1036
23. Stampfer M.J., Krauss R.M., Ma J., Blanche P.J., Holl L.G., Sacks F.M., et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 276:(11):1996;882- 888
24. Gaziano J.M., Hennekens C.H., O'Donnell C.J., Breslow J.L., Buring J.E. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 96:(8):1997;2520-2525
25. Krauss R.M. Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease. Am Heart J. 113:(2 Pt 2):1987;578-582
26. Watts G.F., Mandalia S., Brunt J.N., Slavin B.M., Coltart D.J., Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' atherosclerosis regression study (STARS). Metabolism. 42:(11):1993;1461-1467
27. Phillips N.R., Waters D., Havel R.J. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 88:(6):1993;2762-2770
28. Mack W.J., Krauss R.M., Hodis H.N. Lipoprotein subclasses in the monitored atherosclerosis regression study (MARS): treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol. 16:(5):1996;697-704
29. Hodis H.N., Mack W.J., Dunn M., Liu C., Selzer R.H., Krauss R.M. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation. 95:(8):1997;2022-2026
30. Zilversmit D.B. Atherogenesis: a postprandial phenomenon. Circulation. 60:(3):1979;473-485
31. Patsch J.R., Miesenbock G., Hopferwieser T., Muhlberger V., Knapp E., Dunn J.K., et al. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb. 12:(11):1992;1336-1345
32. Ginsberg H.N., Jones J., Blaner W.S., Thomas A., Karmally W., Fields L., et al. Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler Thromb Vasc Biol. 15:(11):1995;1829-1838
33. Ryu J.E., Howard G., Craven T.E., Bond M.G., Hagaman A.P., Crouse J.R. III. Postprandial triglyceridemia and carotid atherosclerosis in middle-aged subjects. Stroke. 23:(6):1992;823-828
34. Taskinen M.R. Insulin resistance and lipoprotein metabolism. Curr Opin Lipidol. 6:(3):1995;153-160
35. Rapp J.H., Lespine A., Hamilton R.L., Colyvas N., Chaumeton A.H., Tweedie-Hardman J., et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb. 14:(11):1994;1767-1774
36. Alaupovic P., Blackenhorn D.H., Knight-Gibson C., Tavella M., Bard J.M., Shafer D., et al. apoB-containing lipoprotein particles as risk factors for coronary artery disease. Adv Exp Med Biol. 285:1991;299-309
37. Blankenhorn D.H., Alaupovic P., Wickham E., Chin H.P., Azen S.P. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation. 81:(2):1990;470-476
38. Hodis H.N., Mack W.J., Azen S.P., Alaupovic P., Pogoda J.M., LaBree L., et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 90:(1):1994;42-49
39. Sacks F.M., Alaupovic P., Moye L.A., Cole T.G., Sussex B., Stampfer M.J., et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation. 102:(16):2000;1886-1892
40. Lamarche B., St-Pierre A.C., Ruel I.L., Cantin B., Dagenais G.R., Despres J.P. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol. 17:(8):2001;859-865
41. Lamarche B., Tchernof A., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec cardiovascular study. Circulation. 95:(1):1997;69-75
42. St-Pierre A.C., Ruel I.L., Cantin B., Dagenais G.R., Bernard P.M., Despres J.P., et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation. 104:(19):2001;2295-2299
43. Gardner C.D., Fortmann S.P., Krauss R.M. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 276:(11):1996;875-881
44. Mykkanen L., Kuusisto J., Haffner S.M., Laakso M., Austin M.A. LDL size and risk of coronary heart disease in elderly men and women. Arterioscler Thromb Vasc Biol. 19:(11):1999;2742-2748
45. Campos H., Moye L.A., Glasser S.P., Stampfer M.J., Sacks F.M. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA. 286:(12):2001;1468-1474
46. Vakkilainen J., Steiner G., Ansquer J.C., Aubin F., Rattier S., Foucher C., et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the diabetes atherosclerosis intervention study (DAIS). Circulation. 107:(13):2003;1733-1737
47. Williams P.T., Superko H.R., Haskell W.L., Alderman E.L., Blanche P.J., Holl L.G., et al. Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol. 23:(2):2003;314-321
48. Rosenson R.S., Otvos J.D., Freedman D.S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I) trial. Am J Cardiol. 90:(2):2002;89-94
49. Blake G.J., Otvos J.D., Rifai N., Ridker P.M. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 106:(15):2002;1930-1937
50. Miller B.D., Alderman E.L., Haskell W.L., Fair J.M., Krauss R.M. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford coronary risk intervention project. Circulation. 94:(9):1996;2146-2153
51. Zambon A., Hokanson J.E., Brown B.G., Brunzell J.D. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation. 99:(15):1999;1959-1964
52. Campos H., Arnold K.S., Balestra M.E., Innerarity T.L., Krauss R.M. Differences in receptor binding of LDL subfractions. Arterioscler Thromb Vasc Biol. 16:(6):1996;794-801
53. Bjornheden T., Babyi A., Bondjers G., Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis. 123:(1-2):1996;43-56
54. Chait A., Brazg R.L., Tribble D.L., Krauss R.M. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med. 94:(4):1993;350-356
55. Lindgren F.T., Jensen L.C., Hatch F.T. The isolation and quantitative analysis of serum lipoproteins. Nelson G.J. Blood lipids and lipoproteins: quantitation, composition, and metabolism. 1972;181-274 Wiley-Interscience, New York
56. Garvey W.T., Kwon S., Zheng D., Shaughnessy S., Wallace P., Hutto A., et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 52:(2):2003;453-462